Eortc - European Organisation For Research And Treatment Of Cancer company information, Employees & Contact Information

Another Powerful Day at ESMO25 with Denis Lacombe – EORTC Oncodaily

Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets | Scientific Reports Nature

Core outcome sets in cancer clinical trials: current status and future opportunities—an EORTC perspective BioMed Central

Benjamin Besse: Honoured to Have Been Appointed President-Elect of the EORTC Oncodaily

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial | npj Breast Cancer Nature

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics American Association for Cancer Research

Dimensionality and Measurement Invariance of the Italian Version of the EORTC QLQ-C30 in Postoperative Lung Cancer Patients Frontiers

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial ScienceDirect.com

The 6th EORTC Quality of Life in Cancer Clinical Trials Conference Oncodaily

WHO launches new campaign to amplify the lived experience of people affected by cancer World Health Organization (WHO)

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study BioMed Central

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development | Blood Cancer Journal Nature

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junct BMC Cancer

36th EORTC-NCI-AACR Symposium Oncodaily

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers Nature

Highlights from the 36th EORTC-NCI-AACR Symposium 2024 Oncodaily

Elisabeth de Vries and Timothy A. Yap welcome attendees to the EORTC-NCI-AACR Symposium Oncodaily

The 36th ENA Molecular Targets and Cancer Therapeutics Symposium Oncodaily

Registration still open for the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Oncodaily

The EORTC Quality of Life Group Chair, Dr Jaap Reijneveld, opening the group's autumn meeting Oncodaily

The EORTC QLQ-F17 as a shortened version of the EORTC QLQ-C30 to assess self-reported functioning in cancer patients: investigating equivalence and psychometric properties in a randomized cross-over trial The Lancet

HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer Frontiers

EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors Frontiers

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers Nature

Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial ScienceDirect.com

Cancer treatment: Prioritising the patient Innovation News Network

The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life Frontiers

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer Nature

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform Nature

Diving into hot topics of salivary gland carcinoma management—an EORTC young and early career investigator survey Frontiers

Health-related quality of life in women with breast cancer: a review of measures BMC Cancer

Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer BMC Cancer

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy Nature

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer The New England Journal of Medicine

Lomustine and Bevacizumab in Progressive Glioblastoma The New England Journal of Medicine

Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma Frontiers

Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” Trial Frontiers

Patient-reported outcome measures for physical function in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and PROMIS measures using the International Classification of Functioning, Disability and Health BMC Medical Research Methodology

Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer The New England Journal of Medicine

Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours Nature

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab Journal of Nuclear Medicine

Journal of the European Academy of Dermatology and Venereology Wiley Online Library

Hypofractionated volumetric modulated arc therapy with SIB adjuvant to breast preservation surgery: retrospective experience from a Regional Cancer Centre in Eastern India Cambridge University Press & Assessment

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer The New England Journal of Medicine

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer The New England Journal of Medicine

Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, other solid tumors Medical Xpress

Functional health and symptoms in Spain before and during the COVID-19 pandemic BMC Public Health

Duration of Androgen Suppression in the Treatment of Prostate Cancer The New England Journal of Medicine

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma The New England Journal of Medicine